BioAtla, Inc. (BCAB) Q3 2025 Earnings Call Transcript [Seeking Alpha]
BioAtla, Inc. (BCAB)
Company Research
Source: Seeking Alpha
Jay Short - Co-Founder, CEO & Chairman Sheri Lydick - Chief Commercial Officer Eric Sievers - Chief Medical Officer Richard Waldron - Senior VP & CFO Conference Call Participants Julie Miller Yu He - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's BioAtla Third Quarter 2025 Earnings Call. [Operator Instructions] It is now my pleasure to turn the conference over to Julie Miller with LifeSci Advisors. Please go ahead. Julie Miller Thank you, operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; Dr. Eric Sievers, Chief Medical Officer; Sheri Lydick, Chief Commercial Officer; and Richard Waldron, Chief Financial Officer. Earlier this afternoon, BioAtla released financial results and a business update for the quarter ended September 30, 2025. A copy of the press release is available on the company's website. Before we begin, I'd l
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla Enters into Agreements for up to $22.5 Million Flexible FinancingGlobeNewswire
- BioAtla Inc (BCAB) Q3 2025 Earnings Call Highlights: Strategic Partnerships and Promising Trial ... [Yahoo! Finance]Yahoo! Finance
- BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch [Seeking Alpha]Seeking Alpha
- BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue SarcomasGlobeNewswire
- BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025GlobeNewswire
BCAB
Earnings
- 11/13/25 - Beat
BCAB
Sec Filings
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- 12/1/25 - Form 4
- BCAB's page on the SEC website